Genotype-phenotype associations in neurofibromatosis type 1 (NF1): an increased risk of tumor complications in patients with splice-site mutations? by unknown
Alkindy et al. Human Genomics 2012, 6:12
http://www.humgenomics.com/content/6/1/12PRIMARY RESEARCH Open AccessGenotype-phenotype associations in
neurofibromatosis type 1 (NF1): an increased risk
of tumor complications in patients with NF1
splice-site mutations?
Adila Alkindy1, Nadia Chuzhanova2, Usha Kini3, David N Cooper4 and Meena Upadhyaya4*Abstract
Neurofibromatosis type 1 (NF1) is a complex neurocutaneous disorder with an increased susceptibility to develop
both benign and malignant tumors but with a wide spectrum of inter and intrafamilial clinical variability. The
establishment of genotype-phenotype associations in NF1 is potentially useful for targeted therapeutic intervention
but has generally been unsuccessful, apart from small subsets of molecularly defined patients. The objective of this
study was to evaluate the clinical phenotype associated with the specific types of NF1 mutation in a retrospectively
recorded clinical dataset comprising 149 NF1 mutation-known individuals from unrelated families. Each patient was
assessed for ten NF1-related clinical features, including the number of café-au-lait spots, cutaneous and
subcutaneous neurofibromas and the presence/absence of intertriginous skin freckling, Lisch nodules, plexiform and
spinal neurofibromas, optic gliomas, other neoplasms (in particular CNS gliomas, malignant peripheral nerve sheath
tumors (MPNSTs), juvenile myelomonocytic leukemia, rhabdomyosarcoma, phaechromocytoma, gastrointestinal
stromal tumors, juvenile xanthogranuloma, and lipoma) and evidence of learning difficulties. Gender and age at
examination were also recorded. Patients were subcategorized according to their associated NF1 germ line
mutations: frame shift deletions (52), splice-site mutations (23), nonsense mutations (36), missense mutations
(32) and other types of mutation (6). A significant association was apparent between possession of a splice-site
mutation and the presence of brain gliomas and MPNSTs (p= 0.006). If confirmed, these findings are likely to be
clinically important since up to a third of NF1 patients harbor splice-site mutations. A significant influence of gender
was also observed on the number of subcutaneous neurofibromas (females, p= 0.009) and preschool learning
difficulties (females, p= 0.022).
Keywords: Neurofibromatosis type 1, Genotype-phenotype correlation, Malignant peripheral nerve sheath tumors,
Brain glioma, Increased cancer susceptibility, Splice-site mutations, NF1 gene, Gender effectIntroduction
Neurofibromatosis type 1 (NF1) (MIM #162200) [1] is a
common familial cancer syndrome with a prevalence of
1 in 2,500 [2] and an autosomal dominant inheritance
pattern; it is fully penetrant by 5 years of age. NF1 is a
complex disorder that affects many cell types and
involves multiple body systems [3]. The clinical pheno-
typic expression in NF1 is characterized by marked intra* Correspondence: upadhyaya@cardiff.ac.uk
4Institute of Medical Genetics, Cardiff University, Heath Park, Cardiff CF14
4XN, UK
Full list of author information is available at the end of the article
© 2012 Alkindy et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orand interfamilial variability with many NF1 individuals
only relatively mildly affected and their disease is limited
to cutaneous involvement. Most NF1 patients also have
mild learning difficulties. About a quarter of NF1 cases
eventually develop one or more serious clinical multisys-
temic complications that lead to the significant morbid-
ity and increased mortality characteristic of this disorder
[4]. The many NF1-related clinical complications include
neurological, cardiovascular, gastrointestinal, endocrine
and orthopedic features. The overall risk of malignancy
in NF1 is 5% to 15% higher than in the general popula-
tion, the age of onset being earlier and with a poorerLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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primarily involves tumors of the CNS and connective
tissue [5-7].
Neurofibromin, the NF1 gene product, is a large
(2,818 amino acids) [8] ubiquitously expressed protein
present at low levels in most tissues, with the highest
concentration found in the CNS [3,8]. The most inacti-
vating NF1 germ line mutations result in neurofibromin
haploinsufficiency which seriously impairs its key role as
a GTPase-activating protein that down-regulates most
Ras protein activity in the cell [9-11]. Since Ras has a
pivotal role in up-regulating cell proliferation, differenti-
ation, survival and cell death, any functional loss of neu-
rofibromin will result in the inappropriate and sustained
activation of the Ras/Raf/ERK pathway. It is this cellular
dysregulation that explains much of the NF1 clinical
phenotype, especially the increased risk of benign and
malignant neoplasms evident in NF1.
NF1 is however noted for the considerable inter and
intrafamilial variation observed in the clinical phenotype
even in patients who share the same germ line mutation.
As a result, any decisions on surveillance tailored to
some of these potentially treatable complications can be
difficult to implement in the clinic. Successful genetic
counseling is also hampered by clinical complications
that are unpredictable both in severity and progression
even within the same family [4]. This is particularly im-
portant in prenatal genetic counseling where the actual
disease risk to the unborn infant is difficult to predict
and where prenatal diagnosis creates difficulties in re-
productive decision making for the families involved
[4,12]. Hence, given such disease prediction and man-
agement problems, comprehensive genotype-phenotype
studies are warranted.
Unfortunately, attempts to correlate the many and var-
ied germ line NF1 gene mutations with specific clinical
features of NF1 have been largely unsuccessful [13],
mainly due to the marked inter and intrafamilial variability
in disease expression and the extent of the allelic hetero-
geneity underlying the disease. Two potential genotype-
phenotype correlations that involve small subgroups of
NF1 individuals have nevertheless been reported [3,14]. At
least 1,347 different NF1 gene mutations have been identi-
fied [15], many being unique to a specific individual or
family [4,16]; fewer than 20% of NF1 gene lesions are re-
current. As might be expected from the high mutation
rate observed for the human NF1 gene, almost half of all
identified mutations occur de novo [16]. Given the marked
clinical phenotypic variation associated with NF1 even in
individuals carrying the same NF1 mutation, it has been
suggested that feature-specific modifier genes which are
unlinked to the NF1 locus itself, epigenetic alterations or
other environmental factors may also contribute to such
variable expression in NF1 [17,18].The present retrospective study has attempted to as-
sess whether any associated genotype-phenotype correla-
tions could be identified in a large cohort (N= 149) of
clinically well-characterized (but unrelated) NF1 patients
with known pathogenic NF1 mutations.
Methods
Patients
The present study is a retrospective analysis of the clin-
ical data obtained from a cohort of NF1 patients col-
lected for a previous Welsh study that characterized the
NF1 germ line mutations in patients referred from UK-
wide medical genetic centers [19]. This new study was
approved by the local ethical committee, with partici-
pants giving their informed consent. The study cohort
comprised 149 unrelated NF1 germ line mutation-
positive patients whose associated clinical data were
obtained from medical records over the past two years.
The phenotypic information from each patient was gen-
erally recorded in a standardized way. This study actively
excluded all patients known to harbor either a large gen-
omic deletion [14] or the NF1 3-bp in-frame deletion in
exon 17 [3], because both these mutation types have
previously been found to have a tendency to be asso-
ciated with a specific NF1 clinical phenotype.
Patient demographics
The patient cohort was characterized by an equal gender
distribution, an ethnic origin that was predominantly
Caucasian, and an age distribution which ranged from 1
day old to 71 years of age (mean age, 24 years). Most
patients (137, approximately 92%) were clinically diag-
nosed as NF1 according to the National Institutes of
Health (NIH) criteria [20]; three of these patients had con-
current diagnosis of other growth and developmental syn-
dromes; five patients (approximately 3%) were diagnosed
as NF1/Noonan syndrome (MIM #601321), four (approxi-
mately 3%) with NF1, familial spinal (MIM #162210) syn-
drome and three (2%) with Watson syndrome (MIM
#193520). Seven patients (approximately 5%) did not meet
the strict NIH clinical diagnostic criteria for NF1 when
first tested for NF1 mutations, whereas 49 patients (ap-
proximately 33%) had a positive family history of NF1, 90
patients (60%) were sporadic and 10 (approximately 7%)
had an unknown family history. All patient data collected
were anonymized prior to analysis.
Clinical features and associated mutations
Ten major NF1 clinical features were recorded for each
patient, alongside patient age and gender, and the asso-
ciated NF1 germ line mutation. For the purposes of this
analysis, patients were divided into three age groups: <6, 6
to 19 and >19 years. The germ line NF1 mutations were
recorded in terms of the type and specificity of the
Table 1 Prevalence of neoplasms in a cohort (N=149
with known NF1 mutation) of clinically well-characterized
NF1 patients
Type of neoplasm Number of neoplasmsa
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change. These mutations were further subdivided into five
categories (see Figure 1): frame shift mutations (52
patients), splice-site mutations (23 patients), nonsense
mutations (36 patients), missense mutations (32 patients)
and six other less frequent types of mutation, including
in-frame deletions (2), insertion/deletion (indel) mutations
(1), single exon deletions (2) and intragenic multi-exonic
deletions (1). The recorded clinical details included two
numerical features: (1) the number of café-au-lait (CAL)
spots, with four subgroups identified viz., those with no
CALs (ten patients), those with CALs of sizes 1 to 5 mm
(11 cases), patients with CALs of sizes 6 to 99 mm (117)
and four cases with large CALs (>111 mm); and (2) the
number of cutaneous neurofibromas (CNFs) and subcuta-
neous neurofibromas (SCNFs), with patients subgrouped
into those with no neurofibromas, those with only 2 to 5
CNFs, cases with 6 to 99 CNFs and SCNFs, those with
100 to 500 CNFs and SCNFs and those with >500 CNFs.
Seven additional binary (presence or absence) clinical
features were also examined, including skin freckling,
Lisch nodules of the iris, plexiform neurofibromas (PNF),
spinal neurofibromas (SpNF), optic gliomas, rare tumors
known to be commonly associated with NF1 (including
CNS gliomas, malignant peripheral nerve sheath tumors
(MPNSTs), juvenile myelomonocytic leukemia (JMML),
rhabdomyosarcoma, phaechromocytoma, gastrointestinal
stromal tumors (GIST), juvenile xanthogranuloma and
lipoma) and any other type of tumor recorded, and evi-
dence of preschool learning difficulties.
Results
A multinomial logistic regression analysis was performed
using mutation type, age group and gender as covariates,
and the absence of clinical features as a reference (con-
trol) category. The results of this analysis, followingFigure 1 Relative proportion of the different types of mutation
among the germ line NF1 mutations identified.removal of outliers, revealed a highly significant effect of
the mutation type (specifically splice-site mutations) on
the number of CALs, both with 1 to 5 CALs
(p= 1.8 × 10−27) and 6 to 99 CALs (p= 8.5 × 10−43), as
well as for skin freckling (p= 0.028) and neoplasms
(p= 0.006). CNS gliomas and MPNST contributed to
almost half of this group of neoplasms (see Table 1).
For the 6 to 19 years age group, a significant associ-
ation was noted between the presence of a splice-site
mutation and both CNF and SCNF numbers (6 to 99)
(p= 0.002 and p= 0.004 respectively) and the presence of
preschool learning difficulties (p= 0.005). A significant
gender effect (female) was also observed with respect to
SCNF number (6 to 99) (female, p= 0.009) and pre-
school learning difficulties (p= 0.022). This study there-
fore indicates a potential novel NF1 genotype-phenotype
correlation, with NF1 splice-site mutations being signifi-
cantly associated (p= 0.006) with the tendency to de-
velop tumors mostly composed of MPNSTs and CNS
gliomas.Unusual cases
Several patients did not fulfill the strict NIH diagnostic
criteria for NF1 even although they had been found to
harbor NF1 gene mutations. The NIH diagnostic criteria
remain the ‘gold standard’ for NF1 diagnosis, the isolated
occurrence of many of the NF1 features and complica-
tions being thought to be simply sporadic events [4,21].
Thus, NF1 mutation testing is not routinely carried out
unless there is a high index of suspicion of the disorder.
Our findings indicate that such NF1 gene testing, whichreported (%)
CNS gliomas (excluding optic gliomas) 12 8
Malignant peripheral nerve sheath tumor 8 5.5
Rhabdomyosarcoma (prostate) 1 0.7
Medullary thyroid carcinoma 2 1.3
Gastrointestinal stromal tumors 2 1.3
Multiple internal neurofibromas 3 2
Phaechromocytoma 3(1B/L) 2
Colorectal carcinoma at 71 years 1 0.7
Breast cancer - ductal type at 34 and
40 years
2 1.3
Glomus tumor 2 1.3
Xanthogranuloma 2 1.3
Lipoma 4 2.7
Juvenile myelomonocytic leukemia 0 0
aSome of the patients were found to have more than one type of tumor.
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of cases [4,16], should also be considered in the context
of atypical cases. Some examples from the present pa-
tient cohort with identified NF1 mutations include the
following:
(1)An 18-year-old female presenting with an MPNST
of the breast but with no other characteristic NF1
features or complications. Several of her family
members were also reported to have had breast
cancer but they lacked other features of NF1.
(2)A 10-year-old boy with a unilateral optic glioma, a
few small CALs and mild learning difficulties but
with a negative family history of NF1.
(3)NF1 patients with hypertrophic cardiomyopathy
(HCM). In the study cohort, two cases of a father
and his 29-year-old son and a 71-year-old male were
noted to have symptomatic HCM which was
diagnosed by echocardiogram and manifested as
cardiovascular-associated NF1 complications.
Echocardiographic findings of a septal to posterior
left ventricular free wall ratio greater than 1.5
(suggestive of hypertrophic cardiomyopathy) were
noted in at least 4% of NF1 patients [22,23] in oneTable 2 Summary of clinical features and germ line NF1 mutati
Patient ID Sex/age
(years)
Mutation type NIH CNF/
SCNF
PNF
S149 F/24 Missense K1423E Y 0 0
S174 M/adult Missense W1931R Y 0 0
462 F/43 Missense F1193C Y 0 0
482 F/39 Missense W837R Y 0 Y
2198 M/22 Missense M11491 N 0 0
2444 M/24 Missense L1812P Y 0 0
2483 F/29 Nonsense R1748X Y 0 0
2512 M/22 Nonsense R416X Y O Y
2070 F/19 Nonsense R461X Y 0 0
2133 M/51 Nonsense K1517X N 0 0
2199 F/27 Frameshift c.6403insGA N 0 0
2277 F/34 Frameshift c.3721-3722 ins A Y 0 Y
2278 M/39 Frameshift c.7892-7893delAA Y 0 0
1663 M/25 Frameshift c.495delTGTT Y 0 0
26445 F/18 Frameshift c.5406insT Y 0 0
870 F/18 Frameshift c.6219 delT Y 0 0
2276 F/20 Frameshift c.6791insA Y 0 0
2023 F/22 Splice-site c.589-2 A >G ? 0 0
aSome of the patients were found to have more than one type of tumor.study. However, none of the 2,322 NF1 individuals
retrospectively assessed for cardiovascular
malformation in the National Neurofibromatosis
Foundation International Database had HCM [24],
suggesting that routine echocardiography should
form part of the surveillance regimen in NF1. At
least four other single reports of the cooccurrence of
HCM and NF1 [25-28] have appeared in the
literature. Cardiac hypertrophy is the most common
risk factor contributing to cardiovascular mortality
and morbidity in NF1 patients [29]. Congenital heart
disease and cardiomyopathy are also a common
accompaniment of several growth and development
syndromes affecting the RASopathies [30,31].
Cardiomyopathy in these syndromes arises from
increased signaling through Erk1/2 and mTOR
complex 1 [29]. Neurofibromin is known to act in
modulating the epithelial-mesenchymal
transformation and proliferation in the developing
heart by down-regulating RAS activity. In the
absence of functional neurofibromin, mouse
embryonic hearts develop an over-abundance of
endocardial cushion which may obstruct blood
outflow in some cases as a result of cellular
hyperproliferation and a lack of apoptosis [32-34].
The cardiac-specific Nf1 knockout mice, combinedon type in 18 patients lacking peripheral neurofibromas




0 Y B/L axilla Low grade MPNST
0 Y B/L axilla none
0 Y B/L axilla Offspring-same phenotype
0 Y B/L axilla GIST tumor
0 Y N Mild learning difficulties/
CALs onlya
0 Y B/L axilla/groin CNS glioma
0 Y extensive none
0 Y Submammary none
0 Y B/L axilla Unilateral optic glioma
0 Y N CALs onlya
0 Y N Mild learning difficulties/
CALs onlya
0 Y N none
0 Y B/L axilla Mild learning difficulties
0 Y B/L axilla none
0 Y Extensive Mild learning difficulties
0 Y B/L axilla/trunk Bilateral optic glioma
0 Y B/L axilla none
0 Y ? Severe learning difficulties
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important regulator of Ras signaling in cardiac
myocytes, and that Ras activation can lead to
progressive cardiac hypertrophy with associated
pathological changes in adult mice [32,35,36].
(4)NF1 patients with absent CNF and SCNF. In the
study cohort, 18 (12%) unrelated adult patients
lacked peripheral and spinal neurofibromas, and
only three patients had identifiable plexiform
neurofibromas (see Table 2). All patients fulfilled the
strict NIH diagnostic criteria for NF1 except for
three patients who manifested only CALs and mild
learning difficulties. In general, all these patients
exhibited pigmentary changes of NF1 with very few
NF1-related complications and had a milder clinical
phenotype [3,4]. The types of mutations reported in
this group were missense (six patients), nonsense
(four) and microdeletions/microinsertions (seven).
Only a single patient had a splice-site mutation and
severe learning difficulties. Our finding is consistent
with the previous observations, suggesting that the
clinical phenotype of deceased NF1 patients is
characterized by fewer CALs (albeit nonsignificant)
and significantly more neurofibromas [6].
Discussion
NF1 patients with germ line NF1 splice-site mutations
were found to have an increased tendency to develop
MPNSTs and CNS gliomas by comparison with patients
harboring other mutation types, e.g. microinsertions,
microdeletions, nonsense and missense mutations. Up to
30% of all NF1 patients carry germ line NF1 splice-site
mutations, and such mutations often lead to the synthe-
sis of a truncated form of neurofibromin [4,16]. In the
present NF1 patient cohort, however, only 23 individuals
(15%) carried splice-site mutations. This comparatively
low frequency could be explained by the fact that the
current analysis was performed on genomic DNA (rather
than cDNA), and some of the underlying splicing muta-
tions (resulting from deep intronic mutations) could
have been missed if they did not occur in the immediate
vicinity of a splice site. Moreover, some of the missense
or nonsense mutations identified could have exerted an
effect on splicing. Despite the small patient number, our
analyses identified a significant correlation between the
presence of a splice-site mutation and the occurrence of
neoplasms (p= 0.006), mostly brain and connective tis-
sue tumors. This initial finding clearly merits further
clinical investigation in a much larger mutation-known
NF1 patient population. A multicenter study and pro-
spective data collection, based on comprehensive clinical
examination, would be necessary to substantiate this
finding. If our initial conclusion is supported by furtheranalysis, it could imply that the wider application of
RNA-based analyses in NF1 patient screening (in order
to detect splice-site mutations with high efficiency) [33]
might be helpful in predicting which patients would
benefit the most from regular clinical surveillance.
Of all the characteristic features of NF1, the presence
of benign and malignant neoplasm contributes the most
to the morbidity and mortality experienced by many
NF1 individuals; indeed, the overall cancer risk asso-
ciated with NF1 has been reported to be higher than in
the general population in several NF1 studies [5-7],
owing to markedly increased risks of brain and connect-
ive tissue tumors. Indeed, malignancy, alongside other
tumor-related neurological complications, is the most
frequent cause of death in NF1 patients, resulting in a
reduced life expectancy of some 8 to 15 years as com-
pared to the general population [5,7,27]. The predomin-
ance of cancer among causes of death in NF1 is
consistent in most studies [5-7,34,37] and contributes
disproportionately to the mortality in younger age
groups (less than 40 years). This increased risk of malig-
nancy in NF1 individuals is a cause of major concern for
families and is difficult to address during genetic
counseling.
If our finding of an association between the possession
of an NF1 splice-site mutation and the likelihood of
tumor occurrence is borne out by future work, this
group of patients should undergo rigorous clinical sur-
veillance in order to facilitate early diagnosis and permit
early management of any tumor-related complications as
they arise. Although the types of tumors observed in our
patient cohort were heterogeneous, they were similar to
the spectrum of tumors reported in many NF1 patients,
being mainly brain gliomas and MPNSTs [5-7,38] which
comprised almost half of the neoplasms in our cohort.
The prevalence of types of tumors other than the brain
gliomas and MPNSTs reported in this cohort was very
low, as noted in other studies [7]. A moderately
increased susceptibility to develop breast cancer in fe-
male NF1 patients before the age of 50 years has previ-
ously been documented [39]. However, only 2/74 female
(2.7%) cases in our cohort developed ductal type breast
cancer between the ages of 34 and 41 years. Phaechro-
mocytomas and catecholamine-secreting tumors of the
neural crest are rare tumors in the general population
and occur in 0.1% to 5.7% [40] of patients with NF1. In
a recent study, a higher prevalence of 14.7% was noted
[41]. At least three patients (2%) in our cohort had phae-
chromocytoma, whereas two patients had medullary
thyroid cancer, one of these in association with bilateral
phaechromocytoma as part of multiple endocrine neopla-
sia type 2A (MEN2A). The coexistence of MEN2A and
NF1 (the neurocristopathies) has rarely been reported,
suggesting that NF1 patients with phaechromocytoma
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other phaechromocytoma-related syndromes. All three
cases reported in the literature (including our own case)
had identifiable germ line mutations in the NF1 gene, but
not in the RET proto-oncogene which is a known cause of
MEN2A [42]. Colorectal carcinomas have been previously
noted as a cause of death in NF1 [7]. Only one case of
adenocarcinoma of the colon at the age of 71 was noted
in our cohort and this could be a sporadic occurrence.
GIST are mesenchymal tumors of the gastrointestinal tract
and are commonly associated with NF1 and usually with a
good prognosis [43,44]. We report two such tumors in
our cohort. Glomus tumors are small, benign but painful
tumors and are usually associated with NF1 and consid-
ered as part of the tumor spectrum of NF1 [45]. Two
cases of multiple glomus tumors were reported in our co-
hort. Rhabdomyosarcomas are pediatric neoplasms which
are more common in children with NF1 than in the gen-
eral population [46]. One case of a child with rhabdomyo-
sarcoma of the prostate was noted in the study cohort.
Multiple subcutaneous lipomas [47] have been noted in
one patient with NF1. However, solitary lipomas are also
frequent in the general population, and the presence of
these isolated lipomas in four of our patients could be
purely coincidental. The presence of xanthogranulomas in
pediatric NF1 cases may be related to the possible devel-
opment of JMML [48], but none of the patients in our co-
hort had JMML. The prevalence of xanthogranulomas in
the general population of normal children is quite high
(1% to 2%), but these are rarely associated with systemic
manifestations [48].
Our observation of a gender effect in NF1 has not
been previously reported; despite the very similar sex
distribution in our patient cohort, a disproportionate
number of females exhibited learning difficulties
(p= 0.022). Female NF1 patients were also found to be
significantly more likely to manifest SCNFs (p= 0.009).
This observation may relate to the differential effect that
female steroid hormones appear to have on the develop-
ment of CNFs and SCNFs, as previously noted in the
peri-pubertal and pregnant subpopulations of affected
NF1 individuals [49,50]. Peripheral neurofibromas have
also been reported to express progesterone receptors
[49,50] and this could explain the observed gender
effect. SCNFs rarely transform into malignant tumors,
but their presence could be an expression of a more ag-
gressive disease [5,51]. A disproportionate number of
SCNFs in a cohort of NF1 female patients could indicate
a worse prognosis in females in comparison to males, as
indicated in some studies [7,34,51].
Conclusions
Our study suggests a novel potential NF1 genotype-
phenotype correlation, with NF1 splice-site mutationsbeing associated with an increased tendency to develop
neoplasms, mostly composed of CNS gliomas and
MPNSTs. This finding appears to constitute a novel
genotype-phenotype correlation that has the potential to
be clinically useful. Since up to one third of all NF1
patients harbor splice-site mutations, the early detection
of this type of lesion might be helpful in predicting which
patients would benefit the most from regular clinical sur-
veillance, thereby improving their survival. Our study also
supports previous observations of a gender effect on mor-
tality and morbidity associated with NF1; significantly,
more female patients exhibited learning difficulties and
were found to be more likely to possess subcutaneous
neurofibromas than their male counterparts.
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